Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorY. Hamedien_US
dc.contributor.authorM. Nateghpouren_US
dc.contributor.authorP. Tan-ariyaen_US
dc.contributor.authorM. Tiensuwanen_US
dc.contributor.authorU. Silachamroonen_US
dc.contributor.authorS. Looareesuwanen_US
dc.contributor.otherTehran University of Medical Sciencesen_US
dc.contributor.otherMahidol Universityen_US
dc.identifier.citationSoutheast Asian Journal of Tropical Medicine and Public Health. Vol.33, No.3 (2002), 512-518en_US
dc.description.abstractChloroquine-resistant Plasmodium vivax is emerging in Oceania, Asia and Latin America. The drug sensitivity of P. vivax to chloroquine both in vivo and in vitro in the southern part of Iran was assessed: chloroquine-resistant Plasmodium falciparum has already been documented in this area. The in vitro sensitivity of 39 P. vivax isolates was assessed: the mean IC50 and IC90 were 189 ng/ml and 698 ng/ml blood respectively; for in vivo testing, all 39 vivax malaria patients were treated with a standard regimen of chloroquine and followed-up at 28 days: the mean parasite clearance time was 67.2±22.5 hours. The in vitro development of young parasites to mature schizonts in standard test medium was compared with that obtained in McCoy's 5A medium: no significant difference was observed. Synchronization of the blood-stage parasites was performed according to Lambros' method: the method was not suitable because it was detrimental to the parasites. A number of in vitro tests were performed using both our own laboratory-predosed microplates and WHO microplates: there was no significant difference between the results.en_US
dc.rightsMahidol Universityen_US
dc.titlePlasmodium vivax malaria in southeast Iran in 1999-2001: Establishing the response to chloroquine in vitro and in vivoen_US
Appears in Collections:Scopus 2001-2005

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.